1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

27 Dec 2023
Admin
News Article

Everest Medicines Has Received Approval for the New Drug Application (NDA) for Nefecon® in Taiwan, Aimed at Treating Primary IGA Nephropathy in Adult Patients

Everest Medicines has declared that the Taiwan Food and Drug Administration (TFDA) has accepted its New Drug Application (NDA) for Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adult patients. Nefecon® is the first treatment for IgAN approved in the U.S., European Union, and mainland China. The company expects approval in Taiwan in 2024.Rogers Yongqing Luo, CEO of Everest Medicines, expressed satisfaction with the expansion to Taiwan after recent NDA approvals in China and NDA acceptance in South Korea. The Asian population has a high prevalence of IgAN, posing a significant risk of progression to end-stage renal diseases.

Nefecon® received Accelerated Approval Designation (AAD) from the Taiwan FDA in Nov. 2022. The Phase 3 NefIgArd clinical trial demonstrated statistically significant and clinically meaningful benefits of Nefecon® over placebo in preserving kidney function for patients with IgAN.

The full two-year results of the NefIgArd trial, involving 364 patients, showed clinically meaningful preservation of kidney function in both Asian and White subgroups. Everest Medicines aims to offer Nefecon® to patients in various Asian territories in 2024, including Singapore, Hong Kong, Taiwan, and South Korea.

Nefecon® is a patented oral, delayed-release formulation of budesonide, a corticosteroid designed to target mucosal B-cells in the ileum where IgAN originates. Everest Medicines holds exclusive rights to develop and commercialize Nefecon® in Mainland China, Hong Kong, Macau, Taiwan, Singapore, and, as of March 2022, South Korea, through a licensing agreement with Calliditas Therapeutics AB.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!